HC Wainwright Reiterates “Buy” Rating for Talphera (NASDAQ:TLPH)

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $6.00 price target on the stock.

Other analysts have also recently issued reports about the company. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Talphera in a report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 price target on the stock.

Talphera Price Performance

Shares of Talphera stock opened at $0.50 on Tuesday. The firm has a fifty day moving average price of $0.61 and a two-hundred day moving average price of $0.71. Talphera has a fifty-two week low of $0.45 and a fifty-two week high of $1.27. The company has a market cap of $8.43 million, a PE ratio of -0.72 and a beta of 0.20.

Talphera (NASDAQ:TLPH) last released its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.14. Analysts expect that Talphera will post -0.64 earnings per share for the current fiscal year.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.